About Coley Pharmaceutical Group
Coley Pharmaceutical Group, Inc. is an international biopharmaceutical company, headquartered in Wellesley, Massachusetts, USA, that discovers and develops TLR Therapeutics(TM), a new class of investigational drug candidates that direct the human immune system to fight cancers, allergy and asthma disorders and to enhance the effectiveness of vaccines. Coley has established a pipeline of TLR Therapeutic product candidates currently advancing through clinical development with partners and has additional product candidates in preclinical development. Coley has product development, research and license agreements with Pfizer, sanofi-aventis, GlaxoSmithKline, Merck, Novartis Vaccines and the United States government. For further information on Coley Pharmaceutical Group please visit http://www.coleypharma.com.
Safe Harbor Statement
Certain statements in this news release concerning Coley's business are
considered "forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements include, but are
not limited to, those relating to Coley's Rights Plan. Any or all of the
forward-looking statements in this press release may turn out to be wrong.
They can be affected by inaccurate assumptions Coley might make or by known
or unknown risks and uncertainties, including, but not limited to: the
early stage of product development; uncertainties as to the future success
of ongoing and planned clinical trials; the risk that results from early
stage clinical trials may not be indicative of results in later stage
trials; the unproven safety and
|SOURCE Coley Pharmaceutical Group, Inc.|
Copyright©2007 PR Newswire.
All rights reserved